The first casualty of the government’s war on opioid addiction and the prescription drug abuse epidemic is the 77 million people who suffer from chronic non-cancer pain.
On October 4th 2016 the United States Drug Enforcement Administration (DEA) announced the reduction of almost every Schedule II opiate and opioid medication that may be manufactured in the United States in 2017 by 25% or more. There were additional reductions for manufacturing in 2018. This reduction greatly reduces access of opioids for pain relief and penalizes patients who are trying to cope with pain on a daily basis.
Furthermore, the Centers for Disease Control and Prevention (CDC) created a summary of information on opioids and their oral morphine milligram equivalents to provide guidance towards preventing prescription abuse, misuse and overdose. Additionally, the CDC set a limit of 90 morphine milligram equivalents per day per patient. This limit effectively eliminates the majority of the pain relief narcotics currently being prescribed by physicians for 24-hour pain relief.
Even though there is a legitimate clinical need, the CDC limits have made many physicians reluctant to prescribe opioids and the patients are left to suffer.
T Baxter, LLC has created a pain relief program designed to implement precision, personalized tools maximizing patient safety as well as the required pain relief while complying with the CDC statutes.
LoMed provides a proprietary combination of an amplified codeine with drugs that prevent withdrawal from their current opioid, dysphoria and constipation while providing 24 hours of pain relief. Also, due to the nature of codeine LoMed has little to no street value. The economic benefit of LoMed when compared to the currently prescribed opioids is significant. LoMed is ten times safer at half the cost.
The LoMed program gives physicians the tools to individualize pain therapy based on the patient’s ability to avoid respiratory depression, consider their genetic ability to metabolize drugs and to insure there aren’t any conflicting drugs in their system.
The program includes an in-home sleep study to determine the risk of respiratory depression, a pharmacogenomic test to determine the patient’s capacity to metabolize the LoMed proprietary medications and a quarterly toxicology test to confirm the presence of LoMed and the absence of benzodiazepines or other narcotics.
Recently, I prescribed LoMed (120 mg of Codeine, 100 mg Vistaril) to a series of patients I have been treating for chronic non-cancer pain. Each patient successfully transitioned to LoMed without any signs of withdrawal while experiencing similar pain relief.
Each patient was given LoMed II (Colace, Zofran and Neurontin) to prepare their system for codeine and transition from their current opioid. Twenty minutes later, the patients were given LoMed X-tra strength. The patients were monitored for an additional thirty minutes to rule out any side effects.
In addition to the desired pain relief, the initial patient mentioned that he had greater mental clarity and did not experience any breakthrough pain. Additionally, they were able to sleep through the night.
LoMed represents the only significant pain relief medication that successfully treats chronic non-cancer pain and complies with the CDC guidelines and a ray of hope for the 77 million patients overlooked by the government statues.